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The TNF SuperFamily (TNFSF) of ligands include 19
molecules some of which play key roles in the immune
system. All of these ligands are produced as trimeric Type
II membrane molecules that can be released from the cell
surface as single trimers. However, more than a decade of
research has shown that the receptors for TNFSFs on
responding cells require clustering in order to signal.
Thus, single trimers are poor stimuli because they cannot
produce the necessary clustering. Likewise, studies of
agonist anti-TNFSF receptor antibodies (anti-CD40, anti-
4-1BB, anti-DR5, etc.) have shown that these antibodies
must be mounted via their Fc portion to FcRs on an adja-
cent cell in order to cluster and signal these receptors.
This means that agonistic antibodies to TNFSF receptors
only function in microenvironments where there is a
directly adjacent FcR-bearing cell. However, we have
solved the receptor clustering problem by creating fusion
proteins that contain many TNFSF trimers. As scaffolds
for these molecules, we used surfactant protein D (SP-D)
to make molecules with 4 trimeric arms (“UltraLi-
gands™”) and ACRP30 (A Complement-Related Protein
30 kD or adiponectin) to make molecules with 2 trimeric
arms (“MegaLigands™”). Numerous papers from indepen-
dent labs have reported the ability of UltraCD40L™
and MegaCD40L™ to activate human and mouse cells.
UltraOX40L™and MegaOX40L™ have also been studied
and most recently Ultra4-1BBL™ has been produced. We
are applying these unique materials in the following ways:
(1) Using MegaCD40L™ or UltraCD40L™ plus IL-4,
human B cells have been grown from small amounts of
blood to serve as highly efficient APCs for expanding anti-
gen-specific CD8+ T cells in vitro; (2) Mega4-1BBL™ or
Ultra4-1BBL™ are being used to activate TCR-stimulated
CD8+ cytotoxic T cells in vitro; and (3) MegaOX40L™ or
UltraOX40L™ are being used to stimulate CD4+ T cells
in vitro. These cell-free proteins can be used as practical
reagents to simplify and improve the generation of
immune cells for adoptive immunotherapy.
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